Recurrent Adult Immunoblastic Large Cell Lymphoma Terminated Phase 1 / 2 Trials for DB06186 (Ipilimumab)

IndicationStatusPhase
DBCOND0028500 (Recurrent Adult Immunoblastic Large Cell Lymphoma)Terminated1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00089076MDX-010 in Treating Patients With Recurrent or Refractory LymphomaTreatment